Working… Menu
Trial record 1 of 1 for:    02122861
Previous Study | Return to List | Next Study

Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02122861
Recruitment Status : Completed
First Posted : April 25, 2014
Last Update Posted : March 6, 2019
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Immune Design

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : November 14, 2018
Actual Study Completion Date : December 15, 2018